Holen Sie sich die Stockscreener-App
54.58
2.90%
-1.63
Handel nachbörslich:
54.34
-0.24
-0.44%
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Vaxcyte Shares Decline as Capital Research Global Investors Reduces Stake - National Today
Aug PostEarnings: Can Vaxcyte Inc continue delivering strong returnsQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Vaxcyte (NASDAQ:PCVX) CAO Elvia Cowan Sells 2,500 Shares - MarketBeat
Vaxcyte (PCVX) COO logs planned stock sales and RSU tax withholding - Stock Titan
Jefferies Maintains Buy on Vaxcyte (PCVX) March 10, 2026 - Meyka
Jefferies reiterates Vaxcyte stock Buy rating on regulatory clarity By Investing.com - Investing.com Canada
Jefferies reiterates Vaxcyte stock Buy rating on regulatory clarity - Investing.com UK
Understanding the Setup: (PCVX) and Scalable Risk - Stock Traders Daily
Vaxcyte’s Heavy Equity Raise and Wider Losses Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
Neo Ivy Capital Management Has $2.99 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vaxcyte (PCVX) CFO awarded RSUs and options, surrenders shares for taxes - Stock Titan
Vaxcyte (PCVX) CEO receives large RSU and option grants, surrenders shares for tax - Stock Titan
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate - TipRanks
Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte’s VAX-31 Shift the Bull Case (PCVX)? - Yahoo Finance
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. - Yahoo Finance
Vaxcyte, Inc. (PCVX) - DirectorsTalk Interviews
Vaxcyte, Inc. $PCVX Shares Sold by TD Asset Management Inc - MarketBeat
Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists - Yahoo Finance
A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds - Yahoo Finance
Vaxcyte (PCVX) Is Up 5.5% After Unveiling VAX-31 Data, Phase 3 Plans And New FinancingHas The Bull Case Changed? - simplywall.st
Citigroup Inc. Sells 116,206 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
PCVX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Volatility - simplywall.st
Analysts’ Top Healthcare Picks: Vaxcyte (PCVX), TransMedics Group (TMDX) - The Globe and Mail
Westfield Capital Management Co. LP Purchases 663,817 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vanguard Group Inc. Has $443.78 Million Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (PCVX): BTIG Raises Price Target, Maintains Buy Rating | - GuruFocus
JPMorgan Chase & Co. Has $56.37 Million Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans - TipRanks
BTIG raises Vaxcyte price target to $89 on vaccine breadth edge - Investing.com Nigeria
Vaxcyte (NASDAQ:PCVX) Shares Gap Down Following Weak Earnings - MarketBeat
Leerink raises Vaxcyte stock price target on vaccine pipeline expansion By Investing.com - Investing.com Canada
Leerink raises Vaxcyte stock price target on vaccine pipeline expansion - Investing.com Nigeria
Vaxcyte, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ... By GuruFocus - Investing.com Canada
Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and Strategic Advancements - GuruFocus
Vaxcyte Q4 Earnings Call Highlights - MarketBeat
Vaxcyte (NASDAQ:PCVX) Issues Quarterly Earnings Results - MarketBeat
Vaxcyte Q4 2025 Earnings Call Transcript - MarketBeat
Vaxcyte Launches New $500 Million ATM Equity Program - TipRanks
PCVX: VAX-31 advanced in late-stage trials, with strong financials and manufacturing readiness for 2026 - TradingView
Vaxcyte enters into sales agreement, may sell shares of common stock of up to $500 million - marketscreener.com
Vaxcyte Enters Into Sales Agreement, May Sell Shares Of Common Stock Of Up To $500 Million - TradingView
Vaxcyte Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vaxcyte Q4 Loss Widens - marketscreener.com
Vaxcyte (NASDAQ: PCVX) launches $500M common stock sales plan - Stock Titan
Vaxcyte (PCVX) Advances Pneumococcal Vaccine Programs Towards Re - GuruFocus
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
All eyes on Vaxcyte earnings as pneumococcal vaccine nears pivotal data - Investing.com Nigeria
All eyes on Vaxcyte earnings as pneumococcal vaccine nears pivotal data By Investing.com - Investing.com India
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 74% Potential Upside in the Innovative Vaccine Sector - DirectorsTalk Interviews
Earnings Outlook For Vaxcyte - Benzinga
Aug Movers: Whats the RSI of Vaxcyte Inc stockRisk Management & Safe Entry Trade Signal Reports - baoquankhu1.vn
Volume Report: Is Vaxcyte Inc affected by consumer sentiment2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Patterns Watch: What makes UDMY stock attractive todayAnalyst Upgrade & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug Retail: What hedge funds are buying MFS High Yield Municipal TrustDividend Hike & AI Powered Market Trend Analysis - baoquankhu1.vn
Hedge Fund Bets: What is the earnings history of Otter Tail Corporation2025 Technical Patterns & Advanced Swing Trade Entry Plans - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):